Biohaven Pharmaceutical

OverviewSuggest Edit

Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.
TypePrivate
Founded2014
HQNew Haven, CT, US
Websitebiohavenpharma.com

Latest Updates

Employees (est.) (Jun 2021)836
Cybersecurity ratingAMore

Key People/Management at Biohaven Pharmaceutical

Declan Doogan

Declan Doogan

Chairman and Director
Vlad Coric

Vlad Coric

Chief Executive Officer, Director
James Engelhart

James Engelhart

Chief Financial Officer
Kimberly Gentile

Kimberly Gentile

Senior Vice President, Clinical Operations
Gregory H. Bailey

Gregory H. Bailey

Director
Charles Conway

Charles Conway

Chief Scientific Officer
Show more

Biohaven Pharmaceutical Office Locations

Biohaven Pharmaceutical has an office in New Haven
New Haven, CT, US (HQ)
215 Church St
Show all (1)

Biohaven Pharmaceutical Financials and Metrics

Summary Metrics

Founding Date

2014

Biohaven Pharmaceutical total Funding

$80 m

Biohaven Pharmaceutical latest funding size

$80 m

Time since last funding

5 years ago

Biohaven Pharmaceutical investors

Biohaven Pharmaceutical's latest funding round in November 2016 was reported to be $80 m. In total, Biohaven Pharmaceutical has raised $80 m
Show all financial metrics

Biohaven Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Biohaven Pharmaceutical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Biohaven Pharmaceutical Online and Social Media Presence

Embed Graph

Biohaven Pharmaceutical News and Updates

Thinking about trading options or stock in Broadcom, Biohaven Pharmaceutical, Lyft, Occidental Petroleum, or Tesla?

NEW YORK, June 18, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGO, BHVN, LYFT, OXY, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results

NEW HAVEN, Conn., Aug. 14, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported...

Biohaven Pharmaceutical Blogs

BIOHAVEN RECEIVES AUTHORIZATION TO PROCEED FROM FDA AND DOSES FIRST SUBJECT WITH BHV-3500, THIRD-GENERATION, SMALL MOLECULE CGRP-RECEPTOR ANTAGONIST

– BHV-3500 is the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to be administered in an intranasal (IN) formulation in human testing – Nonclinical proof-of-concept with BHV-3500 has been observed in a primate assay and intranasal PK profile offers potential for rap…

BIOHAVEN ACQUIRES OPTION TO LICENSE BIOLOGIC INVESTIGATIONAL AGENT FOR INFLAMMATORY AND AUTOIMMUNE DISEASES FROM THE UNIVERSITY OF CONNECTICUT

Novel anti-metallothionein antibody, UC1MT, has the potential to become a first-in-class treatment for a range of inflammatory and autoimmune disorders   NEW HAVEN, Connecticut, October 9, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it signed an…

BIOHAVEN ANNOUNCES SUBMISSION OF IND FOR BHV-3500, THIRD-GENERATION, SMALL MOLECULE CGRP-RECEPTOR ANTAGONIST FOR THE TREATMENT OF MIGRAINE

– BHV-3500 is the first intranasal (IN) formulation of a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to be advanced for human dosing in clinical trials New Haven, CT  September 12, 2018 — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company…

BIOHAVEN APPOINTS BOB REPELLA TO BOARD OF DIRECTORS

NEW HAVEN, Connecticut, September 11, 2018 /PRNew­­­swire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the appointment of Robert (Bob) Repella to its Board of Directors. Mr. Repella has extensive experience in the pharmaceutical industry, having held executive  manage…

BIOHAVEN PRESENTS AT MIGRAINE TRUST INTERNATIONAL SYMPOSIUM AND HIGHLIGHTS POSITIVE RESULTS FROM STUDY 301 AND STUDY 302 OF RIMEGEPANT, AN ORAL CGRP RECEPTOR ANTAGONIST, IN THE ACUTE TREATMENT OF MIGRAINE

– Both pivotal Phase 3 trials show single-dose rimegepant provides rapid and lasting relief from pain and associated symptoms of migraine – Phase 1 pharmacokinetic study also demonstrates bioequivalence of rimegepant fast-dissolve Zydis® orally dissolving tablet (ODT) with oral tablet formulation us…

BIOHAVEN LICENSES NOVEL MYELOPEROXIDASE INHIBITOR FROM ASTRAZENECA: POTENTIAL FIRST-IN-CLASS TREATMENT FOR MULTIPLE SYSTEM ATROPHY

NEW HAVEN, Connecticut and NEW YORK, New York, September 5, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it entered into an exclusive, worldwide license agreement, through its subsidiary Biohaven Therapeutics Ltd., with AstraZeneca AB for the dev…
Show more

Biohaven Pharmaceutical Frequently Asked Questions

  • When was Biohaven Pharmaceutical founded?

    Biohaven Pharmaceutical was founded in 2014.

  • Who are Biohaven Pharmaceutical key executives?

    Biohaven Pharmaceutical's key executives are Declan Doogan, Vlad Coric and James Engelhart.

  • How many employees does Biohaven Pharmaceutical have?

    Biohaven Pharmaceutical has 836 employees.

  • Who are Biohaven Pharmaceutical competitors?

    Competitors of Biohaven Pharmaceutical include Plasma Industries, Mcneil and The Searle Company.

  • Where is Biohaven Pharmaceutical headquarters?

    Biohaven Pharmaceutical headquarters is located at 215 Church St, New Haven.

  • Where are Biohaven Pharmaceutical offices?

    Biohaven Pharmaceutical has an office in New Haven.

  • How many offices does Biohaven Pharmaceutical have?

    Biohaven Pharmaceutical has 1 office.